دوازپید
Sign in to saveAlso known as MK-329, 3(S)-(-)-1,3-Dihydro-3-(2-indolecarbonylamino)-1-methyl-5-phenyl-2H-(1,4)benzodiazepin-2-one, (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)indole-2-carboxamide, L 364718
Devazepide (L-364,718, MK-329) is benzodiazepine drug, but with quite different actions from most benzodiazepines, lacking affinity for GABAA receptors and instead acting as an CCKA receptor antagonist. It increases appetite and accelerates gastric emptying, and has been suggested as a potential treatment for a variety of gastrointestinal problems including dyspepsia, gastroparesis and gastric reflux. It is also widely used in scientific research into the CCKA receptor.
Research
857 papers- The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.European journal of clinical investigation · 2016
- Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth.Anti-cancer drugs · 2009
- Devazepide, a CCKA receptor antagonist, impairs the acquisition of conditioned reward and conditioned activity.Psychopharmacology · 1996
- Devazepide (L-364718) inhibits growth and increases expression of tumor markers in HT29-S-B6 cells.Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie · 1996
- Devazepide-induced hyperplasia in the rat liver and bile ducts.European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes · 1996
via PubMed